Lexeo Therapeutics (LXEO) Capital Expenditures (2022 - 2026)

Lexeo Therapeutics has reported Capital Expenditures for 5 years, with the latest figure at $35000.0 in Q1 2026.

• Quarterly Capital Expenditures changed N/A year-over-year to $35000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $324000.0 (changed N/A YoY) and the FY2025 annual result came in at $397000.0, down 17.46% from the prior year.
• Capital Expenditures fell to $35000.0 in Q1 2026 per LXEO's latest filing, from $289000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $289000.0 in Q3 2025 and troughed at -$104000.0 in Q4 2022.
• A 5-year average of $81600.0 and a median of $57500.0 in 2023 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2023 and 2024: Capital Expenditures soared 170.19% in 2023, then jumped 1441.67% in 2024.
• Over 5 years, Capital Expenditures stood at -$104000.0 in 2022, then soared by 170.19% to $73000.0 in 2023, then rose by 13.7% to $83000.0 in 2024, then soared by 248.19% to $289000.0 in 2025, then tumbled by 87.89% to $35000.0 in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $35000.0, $289000.0, and $83000.0 for Q1 2026, Q3 2025, and Q3 2024 respectively.